Levetiracetam Tablet, Film Coated, Extended Release
Product Images NDC 50228-190

7 FDA label images from Sciegen Pharmaceuticals, Inc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 50228-190). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sciegen Pharmaceuticals, Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Levetiracetamxr-01 (Levetiracetam Xr 01)

Levetiracetamxr-01 (Levetiracetam Xr 01)
Chemical structure diagram of levetiracetam, the active ingredient in Levetiracetam Extended-Release tablets by ScieGen Pharmaceuticals, Inc. The structure shows a pyrrolidone ring attached to an ethyl group and an amide functional group.*
FDA Label Image

Fig1.jpg (Levetiracetam Fig1)

Fig1.jpg (Levetiracetam Fig1)
A bar chart depicting the percentage of patients for three groups: Placebo (7.4%), Immediate-release levetiracetam 1,000 mg/day (37.1%), and Immediate-release levetiracetam 3,000 mg/day (39.6%). The y-axis represents the percentage of patients, ranging from 0% to 45%.*
FDA Label Image

Fig2.jpg (Levetiracetam Fig2)

Fig2.jpg (Levetiracetam Fig2)
A bar graph showing the percentage of patients experiencing effects for three groups: Placebo (6.3%), Immediate-release levetiracetam 1,000 mg/day (20.8%), and Immediate-release levetiracetam 2,000 mg/day (35.2%). The graph indicates statistically significant differences from placebo for the levetiracetam groups.*
FDA Label Image

Fig3.jpg (Levetiracetam Fig3)

Fig3.jpg (Levetiracetam Fig3)
A bar chart comparing the percentage of patients between placebo and immediate-release levetiracetam at 3,000 mg/day. The placebo group (N=104) shows 14.4% of patients, while the immediate-release levetiracetam group (N=180) shows 39.4%, with a statistically significant difference indicated.*
FDA Label Image

Fig4.jpg (Levetiracetam Fig4)

Fig4.jpg (Levetiracetam Fig4)
A bar chart comparing the percentage of patients between a placebo group (N=97) and an immediate-release levetiracetam tablet group (N=101). The chart shows about 19.6% for placebo and 44.6% for levetiracetam, indicating a statistically significant difference versus placebo.*
FDA Label Image

500mg-60s-label (500mg 60s)

500mg-60s-label (500mg 60s)
Label for Levetiracetam Extended-Release Tablets, USP 500 mg film-coated tablets by ScieGen Pharmaceuticals, Inc. The label indicates a 60-tablet bottle for oral use, with instructions for pharmacist dispensing of the enclosed Medication Guide. Storage instructions and manufacturer information are also provided. The label includes a barcode and dimensions information.*
FDA Label Image

750mg-60s (750mg 60s)

750mg-60s (750mg 60s)
Label for Levetiracetam Extended-Release Tablets, USP, 750 mg by ScieGen Pharmaceuticals, Inc. The film-coated tablet package contains 60 tablets with once daily dosing. The label includes storage instructions, dosage directions to read prescribing information, and a barcode. The label displays the NDC 50228-190-60 and emphasizes pharmacist instructions to dispense the enclosed Medication Guide.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.